ESTRO 38 - Programme Book & Exhibition Guide

POSTERS

> Is there a clinically meaningful change in anatomy during planning of US HDR prostate brachytherapy? A. David, V. Brennan, G. Cohen, A. Damato (USA)

PO-1052

POSTER Brachytherapy: Prostate

> Efficacy/toxicity after high dose rate brachytherapy as monotherapy for localized prostate cancer S. Novikov (Russian Federation), S. Kanaev, M. Gotovchikova, R. Novikov, D. Ilin, M. Girshovitch > LDR versus HDR brachytherapy boost in prostate cancer patients - a retrospective analysis S. Rodda (Canada), L. Murray, D. Bottomley, P. Bownes, C. Wilkinson, E. Adiotomre, B. Al-Qaisieh, E. Dugdale, O. Hulson, J. Mason, J. Smith, A. M Henry > High-dose rate brachytherapy boost for T3 prostate cancer patients: a single instiution experience M. Xu (USA), D. Diao, A. Lazar, K. Shinohara, A. Chang, A. Cunha, I. Hsu > Ultra-Focal Salvage HDR-brachytherapy for recurrent prostate cancer: a single institution experience C. Salembier (Belgium), A. Rijnders, C. Assenmacher, M. Debecker, I. Tshiakatumba, A. Gulyban, O. Michel > Salvage high-dose-brachytherapy for recurrent prostate cancer patients: 10 years of experience P. Lelek (Poland), M. Stankiewicz, T. Krzysztofiak, S. Kellas- Sleczka, M. Fijałkowski, P. Wojcieszek > Long-term outcomes of LDR compared to hypofractionated EBRT for intermediate-risk prostate cancer N. Sanmamed Salgado (Canada), L. Joseph, J. Crook, J. Borg, P. Chung, P. Warde, A. Di Tomasso, A. Berlin, M. Patel, A. Bayley, C. Catton, J. Helou > Separation and rectal dosimetry with a hydrogel spacer inserted during prostate HDR brachytherapy R. Davda (United Kingdom), D. Pendsé, A. Mitra, M. Prentice, L. Melcher, N. Rosenfelder, M. Singhera, R. Patel, M. Boutros, C. Allen, H. Payne

PO-1053

PO-1054

PO-1055

PO-1056

PO-1057

PO-1058

PO-1059

POSTERS AND ELECTRONIC POSTERS | Programme and Exhibition Guide

234